|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
Depts of 1 Pulmonology and 2 Methodology and Statistics and 3 Epidemiology, Maastricht University, Maastrich and 4 Asthma Centre Hornerheide, Horn, the Netherlands
CORRESPONDENCE: A.M.W.J. Schols, Dept of Pulmonology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ, Maastricht. Fax: 31 433875051
Keywords: chronic obstructive pulmonary disease, corticosteroids, survival, systemic administration
Received: February 16, 2000
Accepted October 24, 2000
Systemic corticosteroids are often administered in COPD patients. The relationship between systemic glucocorticoids and mortality in patients with moderate to severe chronic obstructive pulmonary disease (COPD) was retrospectively analysed. Baseline characteristics of the patients, in stable clinical condition, were collected on admission to a pulmonary rehabilitation centre. Overall mortality was asessed at the end of follow-up. The Cox proportional hazards model was used to quantify the relationship between glucocorticoid use, distinguishing administration route (oral/inhalation) and oral dose, and overall mortality, adjusted for the influence of age, sex, smoking, lung function, resting arterial blood gases and body mass index.
On multivariate analysis, oral glucocorticoid use at a (prednisone equivalent) dose of 10 mg·day–1 without inhaled glucocorticoids, was associated with an increased risk (RR=2.34, 95% confidence interval (CI) 1.24–4.44) while 15 mg·day–1 carried a relative risk of 4.03, CI=1.99–8.15). A significant interaction was observed between inhaled and oral glucocorticoid use. Combined with inhaled glucocorticoids, the relative risk of oral glucocorticoid use appeared to be significantly smaller.
It is concluded that in severe chronic obstructive pulmonary disease, maintenance treatment with oral glucocorticoids is associated with increased mortality in a dose-dependent manner. Since the present study design cannot exclude the possibility of bias by indication, further prospective studies are indicated using a broader patient characterization.
This article has been cited by other articles:
|
|
 |
|
  N. Roche Where current pharmacological therapies fall short in COPD: symptom control is not enough Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D D Sin Inhaled corticosteroids and mortality in COPD. Thorax, October 1, 2006; 61(10): 918 - 918. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Matsuyama, H. Mitsuyama, M. Watanabe, K.-i. Oonakahara, I. Higashimoto, M. Osame, and K. Arimura Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD Chest, December 1, 2005; 128(6): 3817 - 3827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF]
|
|
|
|
|
|
N. J. M. Cano, C. Pichard, H. Roth, I. Court-Fortune, L. Cynober, M. Gerard-Boncompain, A. Cuvelier, J.-P. Laaban, J.-C. Melchior, J.-C. Raphael, et al. C-Reactive Protein and Body Mass Index Predict Outcome in End-Stage Respiratory Failure Chest, August 1, 2004; 126(2): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T J Ringbaekl, K Viskuml, and P Lange BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy Chronic Respiratory Disease, April 1, 2004; 1(2): 71 - 78. [Abstract] [PDF]
|
|
|
|
|
|
E. C Creutzberg Factors associated with prognosis in COPD: influence of body composition and systemic corticosteroid use on morbidity and mortality Chronic Respiratory Disease, April 1, 2004; 1(2): 79 - 81. [PDF]
|
|
|
|
 |
|
 The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s. [Full Text] [PDF]
|
|
|
|
|
|
K. H. Groenewegen, A. M.W.J. Schols, and E. F.M. Wouters Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD Chest, August 1, 2003; 124(2): 459 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Croxton, G. G. Weinmann, R. M. Senior, R. A. Wise, J. D. Crapo, and A. S. Buist Clinical Research in Chronic Obstructive Pulmonary Disease: Needs and Opportunities Am. J. Respir. Crit. Care Med., April 15, 2003; 167(8): 1142 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.D. Sin and S.F.P. Man Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur. Respir. J., February 1, 2003; 21(2): 260 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.B. Soriano, J. Vestbo, N.B. Pride, V. Kiri, C. Maden, and W.C. Maier Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Eur. Respir. J., October 1, 2002; 20(4): 819 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.J.M. Cano, H. Roth, I. Court-Fortune, L. Cynober, M. Gerard-Boncompain, A. Cuvelier, J-P. Laaban, J-C. Melchior, C. Pichard, J-C. Raphael, et al. Nutritional depletion in patients on long-term oxygen therapy and/or home mechanical ventilation Eur. Respir. J., July 1, 2002; 20(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |